医学
临床终点
黑色素瘤
内科学
皮疹
不利影响
临床试验
肿瘤科
实体瘤疗效评价标准
临床研究阶段
存活率
无进展生存期
代理终结点
外科
胃肠病学
总体生存率
癌症研究
作者
Richard D. Carvajal,Marcus Otho Butler,Alexander Noor Shoushtari,Jessica C. Hassel,Alexandra P. Ikeguchi,Leonel Fernando Hernandez-Aya,Paul Nathan,Omid Hamid,Josep Maria Piulats,Matthew J. Rioth,Douglas Buckner Johnson,Jason J. Luke,Enrique Espinosa,Serge Leyvraz,Laura E. Collins,Howard Goodall,Koustubh Ranade,Chris Holland,Shaad Essa Abdullah,Joseph J. Sacco
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2022-10-13
卷期号:28 (11): 2364-2373
被引量:186
标识
DOI:10.1038/s41591-022-02015-7
摘要
In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100×CD3), in 127 patients with treatment-refractory metastatic uveal melanoma (NCT02570308). The primary endpoint was the estimation of objective response rate based on RECIST (Response Evaluation Criteria in Solid Tumours) v1.1. Secondary objectives included safety, overall survival, progression-free survival and disease control rate. All patients had at least one treatment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common. Toxicity was mostly mild to moderate in severity but was greatly reduced in incidence and intensity after the initial three doses. Despite a low overall response rate of 5% (95% CI: 2-10%), the 1 year overall survival rate was 62% (95% CI: 53-70%) with a median overall survival of 16.8 months (95% CI: 12.9-21.3), suggesting benefit beyond traditional radiographic-based response criteria. In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly associated with overall survival, even in patients with radiographic progression. Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial.
科研通智能强力驱动
Strongly Powered by AbleSci AI